Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLPGNASDAQ:KNSANASDAQ:TRMLNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLPGGalapagos$24.77-1.4%$25.09$22.36▼$32.17$1.63B0.18258,675 shs183,572 shsKNSAKiniksa Pharmaceuticals$21.77-2.0%$20.84$16.56▼$28.15$1.58B0.48445,055 shs435,902 shsTRMLTourmaline Bio$14.24-6.4%$15.21$11.87▼$29.79$365.75M2.35275,695 shs466,319 shsVERAVera Therapeutics$22.02-8.3%$30.74$21.80▼$51.61$1.40B1.17880,618 shs1.15 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLPGGalapagos-1.34%-3.20%-3.68%-8.65%-21.99%KNSAKiniksa Pharmaceuticals-3.81%-5.13%+9.52%+12.29%+12.57%TRMLTourmaline Bio-8.65%-13.63%+16.20%-25.00%-33.58%VERAVera Therapeutics-9.80%-11.53%-19.75%-43.20%-44.29%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLPGGalapagos0.5248 of 5 stars0.84.00.00.02.10.00.6KNSAKiniksa Pharmaceuticals2.8163 of 5 stars3.51.00.00.03.73.30.6TRMLTourmaline Bio1.9563 of 5 stars3.51.00.00.02.72.50.0VERAVera Therapeutics3.103 of 5 stars3.63.00.00.02.94.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLPGGalapagos 1.50Reduce$25.332.27% UpsideKNSAKiniksa Pharmaceuticals 3.00Buy$37.1770.72% UpsideTRMLTourmaline Bio 3.00Buy$45.20217.42% UpsideVERAVera Therapeutics 3.20Buy$64.67193.67% UpsideCurrent Analyst Ratings BreakdownLatest TRML, VERA, GLPG, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.003/14/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $50.003/13/2025KNSAKiniksa PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.003/6/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.003/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.002/27/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$59.00 ➝ $61.002/25/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$34.002/24/2025TRMLTourmaline BioLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$58.002/14/2025GLPGGalapagosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$31.00 ➝ $22.002/4/2025VERAVera TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$49.002/3/2025VERAVera TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLPGGalapagos$275.65M5.92N/AN/A$47.57 per share0.52KNSAKiniksa Pharmaceuticals$423.24M3.74N/AN/A$6.23 per share3.49TRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A4/23/2025 (Estimated)KNSAKiniksa Pharmaceuticals$14.08M-$0.61N/A87.08N/A-2.36%-7.31%-5.95%4/22/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$2.87N/AN/AN/AN/A-20.97%-20.56%5/12/2025 (Estimated)VERAVera Therapeutics-$95.99M-$2.75N/AN/AN/AN/A-50.13%-39.50%5/8/2025 (Estimated)Latest TRML, VERA, GLPG, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025N/AKNSAKiniksa Pharmaceuticals$0.06N/AN/AN/AN/AN/A3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/A2/25/2025Q4 2024KNSAKiniksa Pharmaceuticals-$0.06-$0.12-$0.06-$0.12$123.42 million$122.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLPGGalapagosN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLPGGalapagosN/A9.979.81KNSAKiniksa PharmaceuticalsN/A3.242.95TRMLTourmaline BioN/A40.3340.33VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLPGGalapagos32.46%KNSAKiniksa Pharmaceuticals53.95%TRMLTourmaline Bio91.89%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipGLPGGalapagos2.91%KNSAKiniksa Pharmaceuticals54.57%TRMLTourmaline Bio11.02%VERAVera Therapeutics21.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLPGGalapagos1,12365.90 million63.98 millionOptionableKNSAKiniksa Pharmaceuticals22072.64 million32.80 millionOptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableTRML, VERA, GLPG, and KNSA HeadlinesRecent News About These CompaniesVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?April 1 at 1:17 PM | marketbeat.comPictet Asset Management Holding SA Boosts Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)April 1 at 4:32 AM | marketbeat.com69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc.March 30 at 3:16 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Hits New 1-Year Low - Should You Sell?March 27, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)March 27, 2025 | markets.businessinsider.comEFG Asset Management North America Corp. Acquires 27,192 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)March 26, 2025 | marketbeat.comSwiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)March 26, 2025 | marketbeat.comPlatinum Investment Management Ltd. Has $5.06 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)March 20, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc.March 20, 2025 | marketbeat.comVictory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)March 14, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Buy" by AnalystsMarch 12, 2025 | marketbeat.comVera Therapeutics (VERA) Expected to Announce Quarterly Earnings on WednesdayMarch 12, 2025 | marketbeat.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 11, 2025 | globenewswire.comFY2025 Earnings Forecast for VERA Issued By HC WainwrightMarch 8, 2025 | marketbeat.comVera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?March 7, 2025 | seekingalpha.comCantor Fitzgerald Has Negative View of VERA FY2025 EarningsMarch 7, 2025 | marketbeat.comCandriam S.C.A. Sells 84,993 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)March 7, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Given New $71.00 Price Target at JPMorgan Chase & Co.March 5, 2025 | marketbeat.comVera Therapeutics price target lowered to $71 from $77 at JPMorganMarch 4, 2025 | markets.businessinsider.comTakeda's $300M bet on Protagonist's blood cancer drug pays off with phase 3 winMarch 4, 2025 | fiercebiotech.comProtagonist Therapeutics price target raised to $57 from $53 at JPMorganMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Iconic Brands Just Announced Bigger Dividend PayoutsBy Leo Miller | March 7, 2025View These 3 Iconic Brands Just Announced Bigger Dividend PayoutsWhy Archer Aviation Stock Could Soar After Palantir PartnershipBy Jeffrey Neal Johnson | March 20, 2025View Why Archer Aviation Stock Could Soar After Palantir Partnership3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?By Ryan Hasson | March 3, 2025View 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?The 5 Most Oversold Stocks on the Market Are… By Thomas Hughes | March 28, 2025View The 5 Most Oversold Stocks on the Market Are… Top 3 Beverage Stocks Pouring Out ProfitsBy Nathan Reiff | March 27, 2025View Top 3 Beverage Stocks Pouring Out ProfitsTRML, VERA, GLPG, and KNSA Company DescriptionsGalapagos NASDAQ:GLPG$24.77 -0.35 (-1.39%) Closing price 04:00 PM EasternExtended Trading$24.55 -0.22 (-0.90%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Kiniksa Pharmaceuticals NASDAQ:KNSA$21.77 -0.44 (-1.98%) Closing price 04:00 PM EasternExtended Trading$21.78 +0.00 (+0.02%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Tourmaline Bio NASDAQ:TRML$14.24 -0.97 (-6.38%) Closing price 04:00 PM EasternExtended Trading$14.24 -0.01 (-0.04%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Vera Therapeutics NASDAQ:VERA$22.02 -2.00 (-8.33%) Closing price 04:00 PM EasternExtended Trading$22.02 +0.00 (+0.02%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
